Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

Cardurion Pharmaceuticals, LLC

Lily Kwok

Mark Sabat

Anthony R Gangloff

Nicholas Scorah

Jerome C Bressi

Haixia Wang

Mallareddy Komandla

Zhiyuan Zhang

Junya Shirai

John David Lawson

Xiaolun Wang

Tomohiro Okawa

Keiko Kakegawa

John S Tyhonas

Minoru Yoshida

Terufumi Takagi

Phong H Vu

Yasufumi Miyamoto

Joanne Miura

Akito Shibuya

Rei Okamoto

Zenyu Shiokawa

Yuta Tanaka

Yoichi Nishikawa

Yoshito Terao

Nobuyuki Matsunaga

Takafumi Yukawa

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Jeffrey Alan Stafford

Michael Brennan Wallace

Zhe Li

Betty Lam

Steven John Woodhead

Walter Keung

Shaosong Chu

Philip Erickson

Sanjib Das

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositionst thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.

Heteroarylamide inhibitors of TBK1

The present invention provides ALK5 inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.

Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5

Compounds of the following formula are provided for use with cMET: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the compounds.

cMET inhibitors

Disclosed are compounds, pharmaceutical compositions, kits, articles of manufacture, methods of using, and methods of preparing compounds having the formula: wherein the variables are as defined herein. The disclosed compounds are inhibitors of Renin.

Renin inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the substituents are as defined herein.

Histone deacetylase inhibitors

Growing community of inventors

San Diego, CA, United States of America

Lily Kwok